Galapagos CEO Henry Gosebruch says the recent uptick in M&A activity is a positive development for the biotech as it pursues ...

Though CMC barriers remain, strategic planning in the early development stages can guide a CGT product to success, noted ...

Aspen Neuroscience has closed a Series C funding round, raising $115m for the clinical development of its cell therapy ...

Alvotech and Advanz Pharma have announced EC marketing authorisations for Gobivaz, a biosimilar to Simponi, across the EEA.

Valo will use its trove of patient records and biobank samples to pinpoint potential targets for Merck’s pipeline expansion.

Innovative linkers, connecting antibodies to payloads, are fine-tuning ADC selectivity while broadening their therapeutic ...

Regeneron has won two US Food and Drug Administration (FDA) approvals for Eylea HD (aflibercept), adding another indication ...

Moderna has announced the expansion of its US manufacturing capabilities with the onshoring of drug product manufacture to ...

Novartis' two new sites in North Carolina fall under the Swiss pharma’s $23bn US manufacturing onshoring ploy.

Redemplo’s approval in familial chylomicronemia syndrome places the drug in competition with Ionis’ Tryngolza.

Alkermes will likely proceed with its planned acquisition of Avadel, which experienced an unexpected hitch following Lundbeck ...

The US FDA has granted approval for AbbVie’s Epkinly to treat adult patients with relapsed or refractory (R/R) follicular ...